ALUR Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -367.88% compared to Allurion Technologies's net margin of -126.59%. Allurion Technologies's return on equity of -- beat Retractable Technologies's return on equity of -26.39%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 280.82%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Allurion Technologies has higher upside potential than Retractable Technologies, analysts believe Allurion Technologies is more attractive than Retractable Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.650, suggesting its more volatile than the S&P 500 by 64.995%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are smaller than Retractable Technologies quarterly revenues of $8.3M. Allurion Technologies's net income of $7.4M is higher than Retractable Technologies's net income of -$10.5M. Notably, Allurion Technologies's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.32x versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -367.88% compared to Allurion Technologies's net margin of -2201.34%. Allurion Technologies's return on equity of -- beat VolitionRX's return on equity of --.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 280.82%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 467.22%. Given that VolitionRX has higher upside potential than Allurion Technologies, analysts believe VolitionRX is more attractive than Allurion Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are larger than VolitionRX quarterly revenues of $246.4K. Allurion Technologies's net income of $7.4M is higher than VolitionRX's net income of -$5.4M. Notably, Allurion Technologies's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.32x versus 35.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -367.88% compared to Allurion Technologies's net margin of -2828.67%. Allurion Technologies's return on equity of -- beat Catheter Precision's return on equity of -137.84%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 280.82%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 733.68%. Given that Catheter Precision has higher upside potential than Allurion Technologies, analysts believe Catheter Precision is more attractive than Allurion Technologies.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are larger than Catheter Precision quarterly revenues of $143K. Allurion Technologies's net income of $7.4M is higher than Catheter Precision's net income of -$4M. Notably, Allurion Technologies's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.32x versus 2.76x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -367.88% compared to Allurion Technologies's net margin of 0.18%. Allurion Technologies's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Allurion Technologies has a consensus price target of $10.63, signalling upside risk potential of 280.82%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 137.51%. Given that Allurion Technologies has higher upside potential than Xtant Medical Holdings, analysts believe Allurion Technologies is more attractive than Xtant Medical Holdings.

Allurion Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Allurion Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allurion Technologies pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Allurion Technologies quarterly revenues are $5.6M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Allurion Technologies's net income of $7.4M is higher than Xtant Medical Holdings's net income of $58K. Notably, Allurion Technologies's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allurion Technologies is 0.32x versus 0.83x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.